Clinical Trials for Drug: TPX-0005

1 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
UCI-16-79 A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) Open